CYP19A1 and breast cancer: At present, hormonal therapies have been extensively applied for the treatment of ERα+ BC, like aromatase inhibitors for suppressing estrogen synthesis and antiestrogens competing with estrogens for the interaction with ERα to hinder ERα signaling pathway, which are the most common cure strategies (57, 58).